Literature DB >> 10206407

Differences between hereditary and sporadic ovarian cancer.

R P Zweemer1, R H Verheijen, F H Menko, J J Gille, P J van Diest, J W Coebergh, P A Shaw, I J Jacobs, P Kenemans.   

Abstract

Approximately 5% of ovarian cancer cases can be attributed to an autosomal dominant inheritance factor. The majority of these cases are due to germline mutations in the BRCA1 or BRCA2 tumoursupressor genes. Patients with hereditary disease do not exhibit pathognomonic features that would allow distinction from non-hereditary (sporadic) cases of ovarian cancer. Our studies are aimed at identifying clinical, histopathological as well as molecular genetic differences between hereditary and sporadic ovarian cancer. Clinical studies of the ovarian cancer cases in 31 families revealed differences regarding age at onset and stage as well as in survival compared with cancer registry controls. The molecular studies of hereditary ovarian cancer are still underway and some preliminary data is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206407     DOI: 10.1016/s0301-2115(98)00218-8

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

1.  Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.

Authors:  P van der Groep; A Bouter; R van der Zanden; I Siccama; F H Menko; J J P Gille; C van Kalken; E van der Wall; R H M Verheijen; P J van Diest
Journal:  J Clin Pathol       Date:  2006-04-07       Impact factor: 3.411

2.  Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.

Authors:  James Yarmolinsky; Caroline J Bull; Emma E Vincent; Jamie Robinson; Axel Walther; George Davey Smith; Sarah J Lewis; Caroline L Relton; Richard M Martin
Journal:  JAMA       Date:  2020-02-18       Impact factor: 56.272

3.  Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Authors:  Jurgen M J Piek; Bas Torrenga; Brenda Hermsen; René H M Verheijen; Ronald P Zweemer; Johan J P Gille; Peter Kenemans; Paul J van Diest; Fred H Menko
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

4.  Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.

Authors:  A P M Jongsma; J M J Piek; R P Zweemer; R H M Verheijen; J W T Klein Gebbinck; G J van Kamp; I J Jacobs; P Shaw; P J van Diest; P Kenemans
Journal:  Mol Pathol       Date:  2002-10

5.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

Review 6.  The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.

Authors:  Chaoyang Sun; Na Li; Dong Ding; Danhui Weng; Li Meng; Gang Chen; Ding Ma
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

7.  Hypodontia phenotype in patients with epithelial ovarian cancer.

Authors:  Anita Fekonja; Andrej Cretnik; Danijel Zerdoner; Iztok Takac
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.